Skip to main content

AS/Spondyloarthritis

    Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow.com First In Class, TYK2 Inhibitor FDA Approved for Psoriasis 2022 New ACR Guidance…
    Update on Axial SpA at #EULAR2022

    This year at EULAR 2022, there were important and interesting topics in Axial Spondy
    1 year 9 months ago
    Update on Axial SpA at #EULAR2022 This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). Dr Antoni Chan shares his picks of abstracts from the conference. https://t.co/AhUC7ORrZi https://t.co/1olLoNS5Ey
    Spondyloarthritis and COVID-19

    With the availability of vaccines and new therapeutics, many of our patients are fully v
    1 year 9 months ago
    Spondyloarthritis and COVID-19 With the availability of vaccines and new therapeutics, many of our patients are fully vaccinated. We know this can limit their chances of severe COVID all while allowing their rheumatic disease to be treated. #EULAR2022 https://t.co/PmQNKYg1Ao https://t.co/N4DJVYJqrL
    This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference. Non-steroidal anti-inflammatory drugs (…
    RT @doctorRBC: New biomarker for atherosclerosis, cardiovascular risk and disease activity in axSpA?
    Low Irisin associat
    1 year 9 months ago
    New biomarker for atherosclerosis, cardiovascular risk and disease activity in axSpA? Low Irisin associated with subclinical atherosclerosis, high CV risk and more severe disease activity in axSpA @RheumNow #EULAR2022 ABST#POS0327
    RT @drdavidliew: Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings.
    1 year 9 months ago
    Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings. Existing MRI scoring may underserve axSpA in women. Added to therapy differences, a lot to readdress for our female axSpA patients. from roundup #EULAR2022 @RheumNow https://t.co/8wCKx9AFcM
    RT @doctorRBC: Gut microbiome of AS patients different from healthy controls. Different bacteria communities may be asso
    1 year 9 months ago
    Gut microbiome of AS patients different from healthy controls. Different bacteria communities may be associated with disease activity. So much more to digest.... @RheumNow #EULAR2022 ABST#POS0330 https://t.co/EAvHngd6SD
    RT @doctorRBC: Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of an
    1 year 9 months ago
    Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts. Note 100% fatigue resolution roughly same vs. placebo @RheumNow #EULAR2022 ABST#POS0305 https://t.co/Doep91QIRa